Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA

Key Points

• Dimensional Fund Advisors increased its Olema Pharmaceuticals stake by 12.9%, acquiring 123,790 shares to own 1.08 million shares worth approximately $16.1 million, or 1.24% of the company.
• Institutional ownership remains high at 91.78%, with several major investors initiating or expanding positions during the latest reporting periods.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $44.10, although OLMA recently traded near $12.05 and remains loss-making.

Dimensional Fund Advisors LP increased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 12.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,082,434 shares of the company's stock after acquiring an additional 123,790 shares during the quarter. Dimensional Fund Advisors LP owned about 1.24% of Olema Pharmaceuticals worth $16,134,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Jennison Associates LLC bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at about $24,100,000. SEB Asset Management AB bought a new position in Olema Pharmaceuticals during the first quarter valued at about $5,061,000. ACT Capital Management LLC acquired a new position in Olema Pharmaceuticals in the 4th quarter valued at approximately $1,338,000. Nicholas Investment Partners LP bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $1,619,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its stake in shares of Olema Pharmaceuticals by 3,237.5% in the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 116,812 shares of the company's stock valued at $1,742,000 after purchasing an additional 113,312 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OLMA has been the topic of several analyst reports. HC Wainwright reissued a "buy" rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Weiss Ratings lowered shares of Olema Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday. Wall Street Zen cut shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, July 25th. Finally, Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Olema Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $44.10.

Olema Pharmaceuticals Stock Up 2.1%

NASDAQ:OLMA opened at $12.05 on Friday. The stock's fifty day moving average price is $11.26 and its two-hundred day moving average price is $15.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -5.97 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a 52-week low of $4.47 and a 52-week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.52). On average, analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Insiders Place Their Bets

In other news, Director Cyrus Harmon sold 12,500 shares of Olema Pharmaceuticals stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director directly owned 715,270 shares of the company's stock, valued at $8,282,826.60. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 12.56% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source